Making Nissui Pharmaceutical as a Wholly-Owned SubsidiaryExpanding the Clinical Testing Business Based on Synergies between Analytical and Measuring Instruments and Culture Media/Reagents Read more
New agreement adds two Telix investigational PET imaging radiotracers to GE Healthcare’s immuno-diagnostic portfolio, to enable patient selection and monitoring in immunotherapy trials Telix tracers evaluate levels of carbonic anhydrase IX and lactate in tumours to inform and improve therapy selection GE Healthcare’s Pharmaceutical Diagnostics business is an established global supplier of PET imaging tracers... Read more
Chicago, U.S. and Barcelona, Spain – October 16, 2022 – At the European Association of Nuclear Medicine (EANM) Annual Meeting, GE Healthcare proudly introduces Omni Legend[i], the first system on its all-new, all-digital PET/CT platform. This cutting-edge system features a brand-new category of digital BGO (dBGO) detector material with a small crystal size that delivers... Read more
Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) Trial also met its first key secondary endpoint, demonstrating higher diagnostic efficacy for [18F]flurpiridaz PET compared to SPECT Myocardial Perfusion Imaging (MPI) With a half-life roughly 12 times longer than currently approved cardiac PET radiotracers, if approved,... Read more
August 03, 2022 HERCULES, Calif.–(BUSINESS WIRE)– Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, S.A. (WSE NewConnect: SCP), a Warsaw, Poland,... Read more